Evidence supporting the use of: Ligandrol
For the health condition: Muscular Dystrophy
Synopsis
Source of validity: Scientific
Rating (out of 5): 2
Ligandrol (LGD-4033) is a selective androgen receptor modulator (SARM) that has been investigated for its potential to treat muscle-wasting conditions, including Muscular Dystrophy. The rationale for its use is rooted in its ability to selectively stimulate androgen receptors in muscle and bone, potentially promoting muscle growth and reducing wasting without the side effects associated with traditional anabolic steroids. Preclinical studies and early-phase clinical trials have shown that Ligandrol can increase lean body mass in healthy volunteers and in patients with muscle-wasting disorders. For example, a Phase I clinical trial (Basaria et al., 2013, J Gerontol A Biol Sci Med Sci) demonstrated that LGD-4033 was well tolerated and resulted in dose-dependent increases in lean body mass in healthy men.
However, direct evidence supporting its efficacy specifically in Muscular Dystrophy patients is limited. Most available studies are small, short-term, and focus on surrogate endpoints such as lean mass rather than functional outcomes or long-term safety. There are currently no approved indications for Ligandrol in Muscular Dystrophy, and further research is needed to establish its clinical effectiveness and safety in this population. As such, while there is a scientific rationale and some preliminary evidence, the overall strength of evidence supporting Ligandrol's use in Muscular Dystrophy remains low.
Other ingredients used for Muscular Dystrophy
acetyl l-carnitinecoenzyme Q10 (CoQ10)
creatine monohydrate
turmeric
omega-3 fatty acids
Urolithin A
vitamin D
Arginine Creatine
Creatine
Other health conditions supported by Ligandrol
Athletic and Exercise AidsBody Building
Broken Bones
Cancer Treatment (reducing side effects)
Convalescence
Exercise
Muscle Tone (lack of)
Muscular Dystrophy
Osteoporosis
Wasting